Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.44
HALO's Cash to Debt is ranked higher than
59% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. HALO: 1.44 )
HALO' s 10-Year Cash to Debt Range
Min: 1.44   Max: No Debt
Current: 1.44

Equity to Asset -0.20
HALO's Equity to Asset is ranked lower than
52% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. HALO: -0.20 )
HALO' s 10-Year Equity to Asset Range
Min: -0.2   Max: 0.89
Current: -0.2

-0.2
0.89
F-Score: 2
Z-Score: -2.17
M-Score: -0.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -146.78
HALO's Operating margin (%) is ranked higher than
65% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. HALO: -146.78 )
HALO' s 10-Year Operating margin (%) Range
Min: -10677.95   Max: -35.37
Current: -146.78

-10677.95
-35.37
Net-margin (%) -152.34
HALO's Net-margin (%) is ranked higher than
64% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. HALO: -152.34 )
HALO' s 10-Year Net-margin (%) Range
Min: -10452.76   Max: -35.25
Current: -152.34

-10452.76
-35.25
ROA (%) -82.01
HALO's ROA (%) is ranked higher than
53% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. HALO: -82.01 )
HALO' s 10-Year ROA (%) Range
Min: -491.34   Max: -23.1
Current: -82.01

-491.34
-23.1
ROC (Joel Greenblatt) (%) -2350.50
HALO's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. HALO: -2350.50 )
HALO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3850.85   Max: -337.67
Current: -2350.5

-3850.85
-337.67
Revenue Growth (%) 51.80
HALO's Revenue Growth (%) is ranked higher than
96% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. HALO: 51.80 )
HALO' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 100
Current: 51.8

0
100
EBITDA Growth (%) 7.70
HALO's EBITDA Growth (%) is ranked higher than
87% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. HALO: 7.70 )
HALO' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 102.7
Current: 7.7

0
102.7
EPS Growth (%) 9.70
HALO's EPS Growth (%) is ranked higher than
87% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. HALO: 9.70 )
HALO' s 10-Year EPS Growth (%) Range
Min: -32.2   Max: 105.4
Current: 9.7

-32.2
105.4
» HALO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

HALO Guru Trades in Q1 2013

Tom Russo 376 sh (New)
Jim Simons 306,922 sh (+90.99%)
Steven Cohen 17,100 sh (+16.75%)
Chuck Royce 83,622 sh (unchged)
» More
Q2 2013

HALO Guru Trades in Q2 2013

Chuck Royce 83,622 sh (unchged)
Tom Russo Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
» More
Q3 2013

HALO Guru Trades in Q3 2013

Murray Stahl 34,555 sh (New)
Chuck Royce 147,697 sh (+76.62%)
» More
Q4 2013

HALO Guru Trades in Q4 2013

Jean-Marie Eveillard 1,294,580 sh (New)
Jim Simons 300,000 sh (New)
Murray Stahl 35,532 sh (+2.83%)
Chuck Royce 112,697 sh (-23.7%)
» More
» Details

Insider Trades

Latest Guru Trades with HALO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-12-31 New Buy0.05%$9.66 - $15.7 $ 7.57-41%1294580
John Burbank 2012-12-31 Sold Out 0.17%$4.82 - $7.07 $ 7.5730%0
John Burbank 2012-09-30 Add 66.67%0.07%$4.28 - $9.78 $ 7.574%500000
John Burbank 2012-06-30 Add 50%0.03%$7.32 - $13 $ 7.57-14%300000
John Burbank 2012-03-31 New Buy0.09%$9.22 - $13.35 $ 7.57-28%200000
George Soros 2011-12-31 Sold Out 0.0018%$5.72 - $9.73 $ 7.57-8%0
George Soros 2011-09-30 New Buy$5.62 - $7.29 $ 7.5714%17100
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 15.58
HALO's P/S is ranked lower than
57% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. HALO: 15.58 )
HALO' s 10-Year P/S Range
Min: 11.07   Max: 461.55
Current: 15.58

11.07
461.55
EV-to-EBIT 5.10
HALO's EV-to-EBIT is ranked higher than
87% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. HALO: 5.10 )
HALO' s 10-Year EV-to-EBIT Range
Min: 109.1   Max: 211.2
Current: 5.1

109.1
211.2

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.40
HALO's Price/Median PS Value is ranked higher than
93% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. HALO: 0.40 )
HALO' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 9.94
Current: 0.4

0.43
9.94
Forward Rate of Return (Yacktman) -10.58
HALO's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. HALO: -10.58 )
HALO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.4   Max: 14.7
Current: -10.58

3.4
14.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RV7.Germany
Halozyme Therapeutics, Inc is a Delaware Corporation. It is a biopharmaceutical company engaged in developing and commercializing products that advance patient care. The Company's research targets the extracellular matrix, an area outside the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. The Company's research focuses mainly on human enzymes that alter the extracellular matrix. The Company's enzyme, the recombinant human hyaluronidase or rHuPH20, temporarily degrades hyaluronan, or HA, a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. It is also developing novel enzymes that may target other matrix structures for therapeutic benefit. The Company's Enhanze technology is the platform for the delivery of proprietary small and large molecules. The Company's operations to date have involved: organizing and staffing its operating subsidiary, Halozyme, Inc.; acquiring, developing and securing its technology; undertaking product development for its existing products and a limited number of product candidates; supporting the development of partnered product candidates; and selling Hylenex recombinant (hyaluronidase human injection). It continues to increase its focus on its proprietary product pipeline and have expanded investments in its proprietary product candidates. It currently has multiple proprietary programs in various stages of research and development. The Company's proprietary program focuses on the formulation of rHuPH20 with prandial (mealtime) insulins for the treatment of diabetes mellitus. Diabetes mellitus is an increasingly prevalent, costly condition associated with substantial morbidity and mortality. Attaining and maintaining normal blood sugar levels to minimize the long-term clinical risks is a key treatment goal for diabetic patients. It has combined rHuPH20 with an analog insulin, e.g., insulin lispro (Humalog), or Lispro-PH20, insulin aspart (Novolog), or Aspart-PH20, and insulin glulisine (Apidra), or each such combination, Analog-PH20, to accelerate their action. These Analog-PH20 combinations facilitate faster insulin dispersion in, and absorption from, the subcutaneous space into the vascular compartment, to faster insulin response. By making mealtime insulin onset faster, i.e., providing earlier insulin to the blood and thus earlier glucose lowering activity, Analog-PH20 may yield an insulin effect, more like that found in healthy, non-diabetic people. It is developing an investigational PEGylated form of rHuPH20, or PEGPH20, a new molecular entity as a candidate for the systemic treatment of tumors that accumulate HA. PEGylation refers to the attachment of polyethylene glycol to rHuPH20, now known as PEGPH20, which converts rHuPH20 from a transient and short-lived enzyme to a more stable entity in blood that can be used to treat systemic disease. HTI-50

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide